### **OPP OFFICIAL RECORD HEALTH EFFECTS DIVISION** SCIENTIFIC DATA REVIEWS **EPA SERIES 361**



# UNITED STATES ENVIRONMENTAL PROTECTION AGENCY WASHINGTON, D.C. 20460

OFFICE OF CHEMICAL SAFETY AND **POLLUTION PREVENTION** 

Date:

December 20, 2011

Subject:

Metaflumizone: Occupational and Residential Exposure/Risk Assessment for

Proposed Use as a Granular Fly Bait

From:

Kelly M. Lowe, Environmental Scientist

Health Effects Division/Risk Assessment Branch 1(7509P)

Thru:

Dana Vogel, Branch Chief

Health Effects Division/Risk Assessment Branch 1(7509P)

To:

John Hebert / Julie Chao, RM 07

Registration Division (7505P)

**PC Code: 281250** 

Decision Nos.: 404129 Petition No.: NA

Risk Assessment Type: Single Chemical

TXR No.: NA MRID No.: NA DP Barcode: D393548

Registration Nos.: 7969-XXX Regulatory Action: Section 3

Case No.: NA

CAS No.: 139968-49-3

40 CFR: §180.XXX

BASF Corporation has proposed a Section 3 Registration for application of metaflumizone as a granular fly bait for control of the adult common housefly around industrial buildings, commercial facilities, and agricultural structures and premises. It can also be used around recreational facilities and outdoor recreational areas. The end-use product is Metaflumizone Fly Bait (EPA Reg #7969-xxx), containing 0.063% active ingredient.

# **Table of Contents**

| 1.0 Executive Summary   | 3  |
|---|----|
| 2.0 Hazard Profile  | 4  |
| 3.0 Use Profile   | 6  |
| 4.0 Residential (Non-Occupational) Exposure/Risk Characterization | 7  |
| 4.1 Residential Handler Exposure                                  | 7  |
| 4.2 Residential Post-application Exposure                         | 8  |
| 5.0 Occupational Exposure/Risk Characterization                   | 12 |
| 5.1 Short- and Intermediate-Term Handler Risk                     | 12 |
| 5.2 Short- and Intermediate-Term Post-Application Risk            | 17 |
| 5.2.1 Dermal Post-Application Risk                                | 17 |
| 5.2.2 Inhalation Post-Application Risk                            | 17 |

# 1.0 Executive Summary

The Health Effects Division (HED) has conducted an occupational exposure assessment for the proposed use of the insecticide active ingredient (a.i.) metaflumizone as a granular fly bait for control of the adult common housefly around industrial buildings, commercial facilities, and agricultural structures and premises. It can also be used around recreational facilities and outdoor recreational areas. The end-use product is Metaflumizone Fly Bait (EPA Reg #7969-xxx), containing 0.063% active ingredient. The bait can be broadcast over large areas as a scatter bait or placed in bait stations/trays. The maximum application rate proposed for broadcast applications (scatter bait) is 0.014 lb ai/A, and for bait stations/trays is 2 oz bait/station hung or placed at a density of 8-10 stations/2000 square feet.

The short- (1-30 days) and intermediate- (1-6 months) term dermal toxicological point of departure is a no-observed-adverse-effect-level (NOAEL) of 100 mg/kg/day identified from a 90-day dermal study in the rat. The short- and intermediate-term inhalation toxicological point of departure is a lowest-observed-adverse-effect-level (LOAEL) of 0.03 mg/L (8 mg/kg/day) identified from a 28-day inhalation study in the rat. The Food Quality Protection Act Safety Factor (FQPA SF) is being retained as an uncertainty factor for the use of a LOAEL in the absence of a NOAEL for *inhalation exposure scenarios*. The total uncertainty factor that has been applied to occupational and residential risk assessments is 100 for short- and intermediate-term dermal exposures and 1000 for short- and intermediate-term inhalation exposures.

The proposed label indicates that the product is not to be applied in locations where children and pets can access or come into contact with the granules; however, the bait can be applied to areas where children and pets would be present, such as recreational facilities and outdoor recreational areas including parks, picnic grounds, and campgrounds. A residential post-application assessment was conducted to assess dermal post-application exposure for adults and children (3 to <6 year olds) and incidental oral exposure for children (3 to <6 year olds). None of the post-application scenarios resulted in risks of concerns (i.e., Margins of Exposure (MOEs) > 100). Metaflumizone is also currently registered as a fire ant bait for use on residential and golf course turf and as a pet spot-on product. An assessment was previously conducted to assess residential handler and post-application exposure/risk from the fire ant bait use and the pet care use. No risks of concern were identified (i.e., MOEs > 100).

The occupational handler assessment for the proposed uses was completed assuming the maximum label application rate. Broadcast applications were assumed to be made by tractor-drawn spreaders, belly grinders, and/or push-type spreaders. Placing bait in bait stations was assumed to be done using a cup/spoon or by hand. Based on the activity use pattern, the duration of exposure is expected to be short-term and intermediate-term for occupational scenarios; long-term exposures (greater than 6 months) are not anticipated based on the proposed use pattern. The same endpoints are used for short- and intermediate-term exposures; therefore, risks are the same for all durations of exposure. The proposed label requires long-sleeved shirt and long pants and chemical-resistant gloves as dermal PPE for all applicators and other handlers.

Occupational handler dermal and inhalation risk estimates were calculated. The dermal and inhalation exposure risks for mixer/loaders, applicators, and mixer/loader/applicators are not of concern (i.e., MOEs >100 for dermal exposures and >1000 for inhalation exposures) at baseline and with the addition of gloves as recommended by the label. Occupational dermal postapplication exposure was not assessed as it is not anticipated that workers will be exposed after application of the fly bait. HED believes the presence of commercial workers in treated areas is minimal after application.

#### Review of Human Research

This risk assessment relies in part on data from studies in which adult human subjects were intentionally exposed to a pesticide to determine their dermal and inhalation exposure. Many such studies, involving exposure to many different pesticides, comprise generic pesticide exposure databases such as the Pesticide Handlers Exposure Database (PHED), the Agricultural Handlers Exposure Task Force (AHETF) and the Agricultural Reentry Task Force (ARTF) Database. EPA has reviewed all the studies in these multi-pesticide generic exposure databases, and on the basis of available evidence has found them to have been neither fundamentally unethical nor significantly deficient relative to standards of ethical research conduct prevailing when they were conducted. There is no regulatory barrier to continued reliance on these studies, and all applicable requirements of EPA's Rule for the Protection of Human Subjects of Research (40 CFR Part 26) have been satisfied.

### 2.0 Hazard Profile

Metaflumizone demonstrated low acute toxicity (Category IV) via the oral, dermal, and inhalation routes. It is neither a dermal irritant (Category IV), eye irritant (Category IV), nor a dermal sensitizer. Table 2.0.1 presents a summary of the acute toxicity information for metaflumizone.

| Table 2.0.1. Acute Toxicity Profile - Me  | taflumizone ' | Technical (96% ai).  |                      |
|---|---------------|--|----------------------|
| Guideline No./Study Type                  | MRID No.      | Results  | Toxicity<br>Category |
| Metaflumizone Technical (96% ai)          |               |  |                      |
| 870.1100/Acute oral toxicity rat          | 46264232      | LD <sub>50</sub> => 5,000 mg/kg (males, females combined)                          | IV                   |
| 870.1100/Acute oral toxicity mouse        | 46264234      | $LD_{50} \Rightarrow 5,000 \text{ mg/kg (males, females combined)}$                | IV                   |
| 870.1200/Acute dermal toxicity rat        | 46264235      | LD <sub>50</sub> > 5,000 mg/kg (males, females combined)                           | IV                   |
| 870.1300/Acute inhalation toxicity rat    | 46264236      | $LC_{50} > 5.2 \text{ mg/L}$ (males, females combined)                             | IV                   |
| 870.2400/Primary eye irritation rabbit    | 46264238      | Conjunctivitis in 2/3, 1/3, 0/3 at 1, 24, and 48 hours, resp.; no positive effects | IV                   |
| 870.2500/Primary dermal irritation rabbit | 46264237      | non-irritant PII = 0   | IV                   |
| 870.2600/Dermal sensitization guinea pig  | 46264239      | is not a sensitizer  | N/A                  |

The short- and intermediate-term incidental oral toxicological point of departure was identified from a 2-generation reproduction study in the rat; where the maternal LOAEL was 50 mg/kg/day based on poor health state and decreased bodyweight. The NOAEL was 20 mg/kg/day.

The short- and intermediate-term dermal toxicological point of departure was identified from a 90-day dermal study in the rat, where the LOAEL was 300 mg/kg/day based on decreased body-weight gain and food consumption in males and females; anogenital smearing, decreased body weight, increased macrophages in the thymus, lymphocyte necrosis in the mesenteric lymph nodes, diffuse atrophy of the mandibular lymph node, and increased hemosiderin in the liver of females. The NOAEL was 100 mg/kg/day.

The short- and intermediate-term inhalation toxicological point of departure was identified from a 28-day inhalation study in the rat, where the LOAEL was 0.03 mg/L (8 mg/kg/day)<sup>1</sup> based on lymphocyte necrosis in the mesenteric lymph node in females.

Metaflumizone was classified as a "not likely" human carcinogen.

A summary of the toxicological endpoints and points of departure chosen for the relevant exposure scenarios for human risk assessment are found in Table 2.0.2.

| Table 2.0.2. Summary<br>Assessment. <sup>1</sup>                                 | y of Toxicological   | Doses and Endpoints for Met  | aflumizone Used in Occupational Exposure   |
|--|--|--|--|
| Exposure Scenario  | Dose Used in<br>Risk<br>Assessment,<br>UF                  | FQPA SF or LOC for Risk<br>Assessment  | Study and Toxicological Effects  |
| Acute Dietary-<br>general population,<br>including infants and<br>children       | N/A  | N/A  | An endpoint of concern (effect) attributable to a single dose was not identified in the database.  Quantification of acute risk to general population including infants and children is not required.  |
| Short- (1-30 days)<br>and Intermediate- (1-<br>6 months) Term<br>Incidental Oral | NOAEL = 20<br>mg/kg/day                                    | LOC (residential) = MOE<br>< 300   | 2-generation reproduction (rat); Maternal LOAEL = 50 mg/kg/day based on poor health state and decreased bodyweight.  |
| Short- (1-30 days)<br>and Intermediate-(1-6<br>months) Term<br>Dermal            | NOAEL = 100<br>mg/kg/day                                   | LOC (residential) = MOE<br>< 100<br>LOC (occupational) =<br>MOE < 100  | 90-day dermal (rat); LOAEL = 300 mg/kg/day based on decreased BW gain and food consumption (M&F); anogenital smearing, decreased BW, increased macrophages in the thymus, lymphocyte necrosis in the mesenteric lymph nodes, diffuse atrophy of the mandibular lymph node, and increased hemosiderin in the liver (F). |
| Short- (1-30 days)<br>and Intermediate-<br>(1-6 months) Term<br>Inhalation       | LOAEL = 0.03<br>mg/L <sup>2</sup><br>NOAEL not<br>observed | LOC (residential) = MOE<br>< 1000<br>(includes 10x FQPA SF in<br>form of UF <sub>L</sub> )<br>LOC (occupational) =<br>MOE < 1000 | 28-day inhalation (rat); LOAEL = 0.03 mg/L* based on lymphocyte necrosis in the mesenteric lymph node (F).   |
| Cancer (oral, dermal, inhalation)  | Classification: 1  | (includes 10x UF <sub>L</sub> )  Not likely to be carcinogenic to  | humans.  |

UF = uncertainty factor, FQPA SF = FQPA Safety Factor, NOAEL = no-observed adverse-effect level, LOAEL = lowest-observed adverse-effect level, MOE = margin of exposure, LOC = level of concern, UF<sub>DB</sub> = database uncertainty factor, UF<sub>L</sub> = uncertainty factor for lack of a NOAEL

<sup>&</sup>lt;sup>1</sup> 0.03 mg/L × 100% absorption × 45.2 L/hr/kg (conversion factor) × 6 hrs/day (exposure duration) × 1 (activity factor) = 8 mg/kg/day

Page 5 of 17

The Agency's level of concern for risks (i.e., target level for MOE) is defined by the uncertainty factors that are applied to the assessment. The Agency typically applies a factor of 10x to account for interspecies extrapolation to humans from the animal test species and another factor of 10x to account for intra-species sensitivity. For the dermal exposure scenarios, the level of concern (LOC) is 100 based on a combined uncertainty factor (UF) of 100 for interspecies (10x) and intraspecies (10x) extrapolation. For the inhalation exposure scenarios, since a NOAEL was not achieved in the 28-day inhalation toxicity study in rats, and this study was the most relevant for inhalation exposure scenarios, the FQPA SF is being retained as an uncertainty factor for the use of a LOAEL in the absence of a NOAEL (UF<sub>L</sub>), resulting in a combined uncertainty factor of 1000. For the incidental oral scenarios, a combined uncertainty factor (UF) of 300 was applied to account for interspecies (10x) and intraspecies (10x) extrapolation and an FQPA SF of 3x to account for the 2-fold greater absorption observed in dietary exposures (see detailed explanation in Memo, K. Lowe *et. al*, D393447).

#### 3.0 Use Profile

The proposed product, Metaflumizone Fly Bait, is a 0.063% active ingredient solid bait formulation to be used as a scatter bait for broadcast treatment or placed in bait stations/trays around industrial buildings, commercial facilities, and agricultural structures and premises. It can also be used around recreational facilities and outdoor recreational areas. Since the proposed use sites are non-agricultural sites, a restricted entry interval (REI) is not specified on the label. The use profile proposed for this Section 3 registration is summarized in Table 3.0.

| Table 3.0. Sumi   | nary of Directions for Use of Metaflumizone.   |
|-------------------|--|
|                   | Outside of food and beverage plants, meat and poultry processing plants, food handling establishments, restaurants, cafes, fast-food establishments, supermarkets, farm markets, bakeries, commissaries, warehouses, and the refuse dumpsters associated with these establishments.    |
| Scatter Bait Use  | Outside of livestock handling and feeding facilities including broiler and layer houses, swine production facilities, livestock barns, horse stables, milking parlors, dairy barns, feed lots, feed storage buildings, feed silos, and other animal handling and feeding facilities.   |
| Sites             | Indoors in livestock handling and feeding facilities. Only in areas where livestock cannot come in contact with or ingest bait granules; such as walkways or manure pits in caged layer houses, dairy barns, and swine facilities.   |
|                   | Outdoors around recreational facilities and outdoor recreational areas including parks, picnic grounds, camp grounds, and outdoor latrines.  |
| Bait station/tray | In and around food and beverage processing plants, meat and poultry processing plants, food handling establishments, restaurants, cafes, fast-food establishments, supermarkets, farm markets, bakeries, commissaries and warehouses.  |
| Use Sites         | In and around livestock handling and feeding facilities including broiler and layer houses, swine production facilities, livestock barns, horse stables, milking parlors, dairy barns, feed lots, feed storage buildings, feed silos and other animal handling and feeding facilities. |

<sup>&</sup>lt;sup>2</sup> 0.03 mg/L x 100% absorption x 45.2 L/hr/kg (conversion factor) x 6 hrs/day (exposure duration) x 1 (activity factor) = 8 mg/kg bw/day

| Table 3.0. Sumn                | nary of Directions for Use of Metaflumizone.   |
|--------------------------------|--|
| Application<br>Timing          | Apply at beginning of season to prevent large infestations and to keep population at manageable levels   |
| Туре                           | Broadcast (scatter bait) or bait stations/trays  |
| Application<br>Method          | Tractor-drawn spreader, push-type spreader, belly grinder, cup/spoon, by hand  |
| Formulation                    | Solid ant bait   |
| [EPA Reg. No.]                 | [7969-xxx]   |
| Maximum                        | Broadcast: 0.014 lb ai/A   |
| Application Rate               | Bait station/tray: 0.000079 lb ai/station and 8-10 stations/2000 ft <sup>2</sup>   |
|                                | Do not apply in side homes. Apply in locations where children and pets cannot access or come into contact with bait granules.                          |
|                                | Do not apply in are where livestock can ingest or contact bait.  |
| Use Directions and Limitations | Do not use (except for bait station use) in edible product areas where food is commercially prepared or process or in serving areas when food exposed. |
|                                | Do not place bait in piles or in wet/moist areas.  |
|                                | Do not pile or heap bait in station or tray.   |
|                                | Reapply as bait is consumed to maintain control.   |

# 4.0 Residential (Non-Occupational) Exposure/Risk Characterization

The proposed product can be used around recreational facilities and outdoor recreational areas including parks, campgrounds and picnic grounds; therefore, there is the potential post-application exposure to adults and children.

In addition, there is an already registered fire ant bait use and pet care use that would result in residential exposure that have been previously assessed (D345154, T. Bloem *et al.*, 26-Jan-2010; D315785, M. Dow, 19-Jan-2006). The fire ant bait product is registered for use on residential and golf course turf. The pet use is a spot-on pet product to control fleas and ticks. It should be noted that the pet use currently registered for metaflumizone is in the process of being cancelled; however, the use has been included in this risk assessment. Existing stock of the registered product will continue to be sold, but registration will not be maintained beyond 2012.

## 4.1 Residential Handler Exposure

The currently proposed product is not intended for homeowner use as it is proposed for commercial/recreational areas, such as campgrounds and picnic grounds. It is expected that commercial handlers would apply this product to areas such as these. Therefore, a residential handler assessment has not been performed for the proposed fly bait product.

For the already registered fire ant bait product, residential handler exposure was assessed for Page 7 of 17

homeowners who apply the fire ant bait products to home lawns. Since the residential and commercial fire ant products have identical application rates, HED used the commercial loader/applicator dermal (no gloves) and inhalation exposure assumptions to calculate exposure and risk estimates for the homeowner loader/applicator scenario (commercial push-type drop spreader; 5 acres/day; only short-term exposures anticipated). Risks were not a concern for residential handlers (i.e., MOEs > the LOC of 100 for dermal exposure and 1000 for inhalation exposure; see Table 4.4).

For the already registered pet care use, exposure/risk from metaflumizone application to domestic pets was not assessed because handler contact is expected to be negligible. The spot-on product is designed to be self-contained as it is applied directly from the tube to the pet with the tip of the applicator used to part the pet's hair.

# 4.2 Residential Post-application Exposure

For the proposed fly bait product, there is the potential for dermal and incidental oral (hand-to-mouth, object-to-mouth, soil ingestion) post-application exposure. Ingestion of metaflumizone granules found in treated areas is also a potential source of exposure for children; however, this scenario is considered an episodic event by HED and is assessed as an acute exposure (i.e., acute dietary endpoints are used). Since there is no acute dietary endpoint applicable to children, no quantitative assessment is needed.

The populations that were considered in the assessment include:

- Residential Adults: these individuals are members of the general population that are exposed to chemicals by engaging in activities at their residences (e.g., in their lawns) and also in areas not limited to their residence (e.g., golf courses or parks) previously treated with a pesticide. These kinds of exposures are attributable to a variety of activities and are usually addressed by HED in risk assessments by considering a representative activity as the basis for the exposure calculation.
- Residential Children: children are members of the general population that can also be exposed in their residences (e.g., on lawns and other residential turfgrass areas). These kinds of exposures are attributable to a variety of activities such as playing outside. Three to >6 year olds have been selected as the representative population for lawn turf assessments.

Postapplication exposure scenarios were developed for each residential setting where metaflumizone can be used. The scenarios likely to result in postapplication exposures are as follows:

- Dermal exposure from residue on lawns (adult, 3 to <6 year olds);
- Hand-to-mouth transfer of residues on lawns (3 to <6 year olds);

- Object-to-mouth transfer of residues on lawns (3 to <6 year olds); and
- Incidental ingestion of soil from pesticide-treated residential areas (3 to <6 year olds).

The following equations were used to calculate postapplication risks:

(1) Dermal Exposure from Residue on Treated Lawns and Golf Course Turf (adults and 3 to <6 year olds)

```
ADD = (TTR_0 * ET * TC * CF1) / BW
```

#### Where:

```
ADD = average daily dose (mg/kg/day);
```

TTR<sub>0</sub> = turf transferable residue on day "0" ( $\mu$ g/cm<sup>2</sup>). TTR = application rate ( $\mu$ g/cm<sup>2</sup>) \* fraction

of ai retained on foliage (5% for turf activities);

ET = exposure time (2 hr/day for high contact activities);

TC = transfer coefficient (14,500 cm<sup>2</sup>/hr for adults and 5,200 cm<sup>2</sup>/hr for 3 to <6 year olds high contact

activities);

CF1 = conversion factor (0.001 mg/ $\mu$ g); and

BW = body weight (60 kg for adults and 15 kg for 3 to <6 year olds).

(2) Hand-to-mouth Transfer of Pesticide Residues on Lawns (3 to <6 year olds)

```
ADD = (TTR_0 * SA * FQ * ET * SE * CF1) / BW
```

#### Where:

```
ADD = average daily dose (mg/kg/day);
```

TTRt = turf transferable residue on day "0" ( $\mu$ g/cm<sup>2</sup>);

SA = surface area of the hands (20 cm<sup>2</sup>/event);

FQ = frequency of hand-to-mouth activity (20 events/hr);

ET = exposure time (2 hr/day); SE = extraction by saliva (50%);

CF1 = conversion factor (0.001 mg/ $\mu$ g); and

BW = body weight (15 kg).

(3) Object-to-mouth Transfer of Pesticide Residues on Lawns (3 to <6 year olds).

```
ADD = (TTR_0 * IgR* CF1) / BW
```

#### Where:

ADD = average daily dose (mg/kg/day);

 $TTR_t = turf transferable residue on day "0" (µg/cm<sup>2</sup>);$ 

IgR = ingestion rate of grass (25 cm<sup>2</sup>/day); CF1 = conversion factor (1E-3 mg/ug); and

BW = body weight (15 kg).

# (4) Incidental Ingestion of Soil from Pesticide-Treated Residential Areas (3 to < 6 year olds)

$$ADD = (SR_0 * IgR * CF1) / BW$$

Where:

ADD = average daily dose (mg/kg/day);  $SR_0$  = soil residue on day "0" (0.0022  $\mu$ g/g); IgR = ingestion rate of soil (100 mg/day); CF1 = conversion factor (1E-6 g/ $\mu$ g); and BW = body weight (15 kg).

and

 $SR_t = TTRt * F * CF2$ 

Where:

 $TTR_t$  = turf transferable residue on day "0" ( $\mu g/cm^2$ );

F = fraction of ai available in uppermost cm of soil (1 fraction/cm); and

CF2 = conversion factor (0.67 cm<sup>3</sup>/g soil).

Table 4.2 presents the postapplication MOE values calculated for adults and 3 to <6 year olds after applications of metaflumizone. Postapplication noncancer risks do not exceed HED's level of concern for any of the scenarios assessed.

| Table 4.2. Residential Risk Estimates for Po | ostapplicat       | ion Exposure                               |                                  |                      |  |
|--|-------------------|--|----------------------------------|----------------------|--|
| Exposure Scenario                            | Route of Exposure | Dermal Transfer<br>Coefficient<br>(cm²/hr) | Application<br>Rate (lb ai/acre) | Dose<br>(mg/kg/day)  | MOE at Day 0<br>(Level of Concern<br>= 100) <sup>e</sup> |
| Adults                                       |                   |  |                                  |                      |  |
| Residential Turf (High Contact Activities)   | Dermal            | 14,500                                     | 0.014                            | 0.0033 a             | 31,000   |
| 3 to <6 year olds                            |                   |  |                                  |                      |  |
| Residential Turf (High Contact Activities)   | Dermal            | 5,200                                      |                                  | 0.0054 a             | 18,000   |
| Hand to Mouth Activity on Turf               |                   |  | 0.014                            | 0.00021 <sup>b</sup> | 96,000   |
| Object to Mouth Activity on Turf             | Oral              | NA   | 0.014                            | 0.000052°            | 380,000  |
| Incidental Soil Ingestion                    | ]                 |  |                                  | $0.0000007^{d}$      | 29,000,000   |

a. Dermal dose (mg/kg/day) = application rate (lb ai/A) \* fraction of ai retained on foliage (5%) \* exposure time (2 hr) \* dermal transfer coefficient (cm2/hr) \* 0.001 mg/µg \* 4.5E08 ug/lb \* 2.47E-08 A/cm2) / body weight (70 kg for adults and 15 kg for 3 to<6 year olds).

Use of the already registered fire ant products may also result in short-term post-application exposure to children (3 to <6 year olds; dermal and incidental oral), adults (dermal), and adolescents (dermal). Ingestion of metaflumizone granules found in treated lawns or gardens is also a potential source of exposure for children. This scenario is considered an episodic event by

b. Hand to Mouth dose (mg/kg/day) = application rate (lb ai/A) \* fraction of ai retained on foliage (5%) \* surface area mouthed (20 cm2/event) \* frequency of mouthing (20 events/hr) \* exposure time (2 hr) \* saliva extraction (0.50) \* 0.001 mg/µg \* 4.5E08 ug/lb \* 2.47E-08 A/cm2) / body weight (15 kg for 3 to<6 year olds).

c. Object to Mouth dose (mg/kg/day) = application rate (lb ai/A) \* fraction of ai retained on foliage (5%) \* ingestion rate of grass (25 cm²/day)\* 0.001 mg/ug) / body weight (15 kg for 3 to<6 year olds).

d. Soil ingestion dose (mg/kg/day) = application rate (lb ai/A) \* fraction of ai retained on foliage (5%) \* fraction of ai available in uppermost cm of soil (1 fraction/cm) \* 0.67 cm<sup>3</sup>/g soil \* ingestion rate of soil (100 mg/day) \* 1E-6 g/ $\mu$ g) / body weight (15 kg for 3 to<6 year olds)

e. MOE = NOAEL / Dose where dermal NOAEL = 100 mg/kg/day and incidental oral NOAEL = 20 mg/kg/day.

HED and, therefore, is assessed as an acute exposure (i.e., acute dietary endpoints are used). Since there is no acute dietary endpoint applicable to children, no quantitative assessment is needed. The resulting dermal and incidental oral MOEs are greater than the LOC of 100 and 300, respectively, and, therefore, are not of concern (see Table 4.4).

The pet care products may also result in post-application dermal (all populations) and incidental oral [children (3 to <6 year olds)] exposures. The resulting MOEs are >100 for dermal exposures and >300 for incidental oral exposures, and, therefore, exceed HED's LOC (see Table 4.4). HED notes that pet care product exposure calculations can be considered refined in that they are based on the assumptions that 0.78% of the application rate is available as dislodgeable residue rather than the default 20%; for further information see D315785 (M. Dow, 19-Jan-2006).

# 4.4 Combined Residential Exposure

For residential handlers, dermal and inhalation exposures are combined since the endpoints are similar for these routes. For children (3 to <6 year olds), post-application hand-to-mouth and dermal exposures are combined. Dermal exposure could be combined with all the incidental oral exposure scenarios (e.g., hand-to-mouth, object-to-mouth, soil ingestion) since it is assumed that these exposures do not occur as single, isolated events, but rather as a series of concurrent events that may overlap. However, combining all of the incidental oral exposures with dermal exposure would be overly conservative because each of these scenarios, independently, incorporates highend, health protective inputs or assumptions. Combining post-application dermal exposure with only hand-to-mouth exposure is considered a protective estimate of children's exposure to pesticides used in residential settings.

Since the LOCs for the dermal, inhalation and incidental oral routes are not the same (dermal LOC = 100, inhalation LOC = 1000, and incidental oral LOC = 300), these routes were combined using the aggregate risk index (ARI) approach.

| Table 4.4. Summary of Short-te           | rm Residential Handler and Post-ap                    | plication Exposures | and Risks.       |
|--|---|---------------------|------------------|
| Population                               | Route of Exposure                                     | Dose (mg/kg/day)    | MOE <sup>1</sup> |
| Fire Ant Bait (registered on law         | ns, landscapes, golf courses, and othe                | r non-cropland; D3  | 45154/D315785)   |
|  | Dermal  | 0.00021             | 480,000          |
| Adult Residential Handler                | Inhalation  | 0.00000045          | 18,000,000       |
|  | Combined dermal and inhalation                        |                     | $ARI^2 = 3,800$  |
| Adult – Residential Post-<br>application | Dermal  | 0.000232            | 430,000          |
| Adult – Golfer Post-application          | Dermal  | 0.000016            | 6,200,000        |
| Adolescent – Golfer Post-<br>application | Dermal  | 0.0000272           | 3,700,000        |
|  | Incidental oral hand-to-mouth                         | 0.000015            | 1,300,000        |
| Cl. 111 (2 to c6                         | Incidental oral object-to-mouth                       | 0.00000093          | 22,000,000       |
| Children (3 to <6 year olds) –           | Dermal  | 0.00039             | 260,000          |
| Post-application                         | Combined incidental oral hand-to-<br>mouth and dermal | -                   | $ARI^3 = 1,600$  |

| Table 4.4. Summary of Short-te   | rm Residential Handler and Post-ap                    | plication Exposures | and Risks.       |
|----------------------------------|---|---------------------|------------------|
| Population                       | Route of Exposure                                     | Dose (mg/kg/day)    | MOE <sup>1</sup> |
| Pet Care (registered spot-on; D3 | 45154/D315785)  |                     |                  |
| Adults - Post-application        | Dermal  | 0.29                | 340              |
|                                  | Incidental oral hand-to-mouth                         | 0.035               | 570              |
| Children (3 to <6 year olds) –   | Dermal  | 0.16                | 620              |
| Post-application                 | Combined incidental oral hand-to-<br>mouth and dermal | _                   | $ARI^3 = 1.5$    |
| Fly Bait (proposed; D393548)     |   |                     |                  |
| Adult -Post-application          | Dermal  | 0.0033              | 31,000           |
|                                  | Incidental oral hand-to-mouth                         | 0.00021             | 96,000           |
|                                  | Incidental oral object-to-mouth                       | 0.000052            | 380,000          |
| Children (3 to <6 year olds) –   | Incidental soil ingestion                             | 0.0000007           | 29,000,000       |
| Post-application                 | Dermal  | 0.0054              | 18,000           |
|                                  | Combined incidental oral hand-to-<br>mouth and dermal |                     | $ARI^3 = 120$    |

<sup>1.</sup>  $MOE = NOAEL (mg/kg/day) \div Dose (mg/kg/day)$ .

# 5.0 Occupational Exposure/Risk Characterization

#### 5.1 Short- and Intermediate-Term Handler Risk

Based on the anticipated use patterns and current labeling, types of equipment and techniques that can potentially be used, occupational handler exposure is expected from the proposed uses. The quantitative exposure/risk assessment developed for occupational handlers is based on the following scenarios:

#### Mixer/Loader:

(1) loading granules for tractor-drawn spreader applications,

## Applicator:

- (2) applying granules via tractor-drawn spreader,
- (3) applying granules by hand,

## Mixer/Loader/Applicator:

- (4) loading/applying granules via "push type" rotary spreader,
- (5) applying ready-to-use granules by spoon (Proprietary study), and
- (6) loading/applying granules via belly grinder.

For pesticide handlers, HED presents estimates of dermal exposure for "baseline" (i.e., workers wearing a single layer of work clothing consisting of a long sleeved shirt, long pants, shoes plus socks and no protective gloves), as well as for "baseline" and the use of protective gloves or other personal protective equipment (PPE), as might be necessary. The metaflumizone product labels direct mixers, loaders, applicators and other handlers to wear long-sleeved shirt and long

<sup>2.</sup> ARI = Aggregate Risk Index = 1 ÷ ((1 ÷ (MOE<sub>inhalation</sub> ÷ LOC<sub>inhalation</sub>)) + (1 ÷ (MOE<sub>dermal</sub> ÷ LOC<sub>dermal</sub>))); ARI > 1 indicates an acceptable exposure

<sup>3.</sup>  $A\ddot{R}I = Aggregate \ Risk \ Index = 1 \div ((1 \div (MOE_{incidental \ oral \ hand-to-mouth} \div LOC_{incidental \ oral \ hand-to-mouth})) + (1 \div (MOE_{dermal} \div LOC_{dermal}))); \ ARI > 1$  indicates an acceptable exposure.

pants, chemical-resistant gloves, and shoes plus socks.

No chemical-specific handler exposure data were submitted in support of this Section 3 registration. One proprietary study was available to use as surrogate data for the spoon/cup scenario. The study used for the spoon scenario is described below. For the other scenarios assessed, HED has relied on the most scientifically-reliable surrogate data currently available from various sources such as the Pesticide Handler Exposure Database (PHED), the Agricultural Handler Exposure Task Force (AHETF), and the Outdoor Residential Exposure Task Force (ORETF). Some of this data, such as the industry task force data, is compensatory, subject to the data protection provisions of FIFRA. HED policy on use of surrogate data is described in more detail on the Agency's website (http://www.epa.gov/pesticides/science/handler-exposure-data.html). Scenario-specific surrogate exposure data, including their sources, are presented in the "Occupational Pesticide Handler Unit Exposure Surrogate Reference Table" (http://www.epa.gov/pesticides/science/handler-exposure-table.pdf).

# Proprietary study

Worker Exposure Study During Application of Regent 20GR In Banana Plantation, EPA MRID 452507-02 (Fipronil Study): Exposure during the application of a granular formulation of the insecticide, fipronil (i.e., Regent 20GR), was monitored during spoon applications to bananas for control of insects, mites, and nematodes. A total of 10 mixer/loader/applicator events spoon application to bananas were monitored during applications on two different days in June, 1994, on the same banana plantation in Cameroon. The replicates were as follows: 6 spoon/hand applications on day 1; and 4 spoon/hand applications on day 2. Weather was typical of the application season in that it was hot and humid.

Monitoring was completed using whole body dosimeters, cotton gloves, cotton caps, and personal sampling pumps equipped with filters. Regent 20GR was supplied in 22 pound boxes, which were loaded directly into buckets for the spoon applicators. The application rate for fipronil used in this study is 7.5 grams of Regent 20GR (i.e., 0.15 grams ai/plant), which is equivalent to about 0.26 lb ai/acre (0.00033 lb ai/plant) at approximately 800 plants per acre. The numbers of acres treated ranged from approximately 0.75 to 1 acre. The pounds of active ingredient handled ranged from about a quarter to half a pound per replicate.

Each applicator wore whole body dosimeters that also served as the normal work clothing. PVC gloves were also worn over cotton gloves which served as the dosimeters. A protection factor of 50 percent was used by the Agency to calculate exposure levels under a layer of normal work clothing. Dosimeter samples were segmented into arms, legs, and torso for analysis.

| Unit Exposure Values Obtained From | om MRID 452507-02                                |                                    |
|------------------------------------|--|------------------------------------|
| Scenario Monitored                 | Dermal (mg exp./lb ai handled)                   | T-1-1-4: (                         |
| Scenario Monitored                 | Single Layer Clothing (short sleeves and shorts) | Inhalation (µg exp./lb ai handled) |
| Applications with a Spoon          | 3.5  | 45                                 |

This fipronil study is considered to be an appropriate source of surrogate handler exposure data because formulation types are similar (granular) and application methods are similar (applying granulars with a spoon) to the proposed use. The study is considered to be of sufficient quality for use in risk assessment. Data compensation for these data should be determined.

Typically, HED completes short- and intermediate-term assessments for occupational scenarios

in all cases because these kinds of exposures are likely and acceptable use/usage data are not available to justify deleting intermediate-term scenarios. Based on use data and label instructions, HED believes that occupational exposures may occur over a single day or up to weeks at a time for many use-patterns and that intermittent exposure over several weeks may also occur. Some applicators may apply these products over a period of weeks, because they are commercial applicators who are completing multiple applications for multiple clients. Long-term exposures are not expected, therefore, a long-term assessment was not conducted.

The daily areas treated were defined for each handler scenario (in appropriate units) by determining the amount that can be reasonably treated in a single day. When possible, the assumptions for daily areas treated are taken from the HED's ExpoSAC Policy #9: "Standard Values for Daily Acres Treated in Agriculture", which was revised on July 5, 2000. Values used for area treated in each scenario include: 40 acres for applications with tractor drawn spreader, 5 acres for "push-type" spreader applications, 1 acre for belly grinder applications, and 10 bait stations for placement of bait in stations/trays either via cup/spoon or hand.

A dermal-absorption factor was not needed since the dermal point of departure is based on a dermal study. An inhalation absorption factor of 100% for extrapolation from an oral exposure to an inhalation exposure was assumed. A body weight of 70 kg was used since the endpoints were not related to developmental effects. Daily dermal or inhalation handler exposures are estimated for each applicable handler task with the application rate, the area treated in a day, and the applicable dermal or inhalation unit exposure using the following formula:

Daily Exposure = Unit Exposure × Application Rate × Daily Area Treated

#### Where:

Daily Exposure = Amount (mg/day) deposited on the surface of the skin that is available for dermal

absorption or amount inhaled that is available for inhalation absorption;

Unit Exposure = Unit exposure value (mg/lb ai) derived from August 1998 PHED data;

Application Rate = Normalized application rate based on a logical unit treatment, such as acres (A);

and

Daily Area Treated = Normalized application area based on a logical unit treatment such as acres

(A/day).

The daily dermal or inhalation dose is calculated by normalizing the daily exposure by body weight and adjusting, if necessary, with an appropriate dermal or inhalation absorption factor using the following formula:

Average Daily Dose = Daily Exposure  $\times$  Absorption Factor  $\div$  Body Weight

### Where:

Average Daily Dose = Absorbed dose received from exposure to a pesticide in a given scenario (mg/kg/day);

Daily Exposure = Amount (mg/day) deposited on the surface of the skin that is available for dermal

absorption or amount inhaled that is available for inhalation absorption;

Absorption Factor = A measure of the amount of chemical that crosses a biological boundary such as

the skin or lungs (% of the total available absorbed); and

Body Weight = Body weight determined to represent the population of interest in a risk

assessment (kg).

Dermal and inhalation risks were combined in this assessment, since the toxicological effects for these exposure routes were similar. A total aggregated risk index (ARI) was used since the target MOE values for dermal exposure (100) and inhalation exposure (1000) are different. The target ARI is 1; therefore, ARIs of less than 1 are risks of concern. The aggregate risk index (ARI) was calculated as follows.

Aggregate Risk Index (ARI) =  $1 \div (1 \div RI_{dermal}) + (1 \div RI_{inhalation})$ 

#### Where:

 $Risk\ Index\ (RI) = MOE \div Uncertainty\ Factor$ 

Table 5.1.1 presents the exposure/risks for short and intermediate-term dermal and inhalation exposures at baseline and with the addition of gloves as personal protective equipment as recommended on the label. The dermal and inhalation exposure risks for mixer/loaders, applicators and mixer/loader/applicators are not of concern (i.e., MOEs >100 for dermal and >1000 for inhalation; ARIs > 1) at baseline and with the addition of gloves.

|  |                         |   | _   | _                                |   |                               |                  |                               |                  |                  |
|--|-------------------------|---|---|----------------------------------|---|-------------------------------|------------------|-------------------------------|------------------|------------------|
| Exposure Scenario  | Mitigation <sup>1</sup> | Dermal<br>Unit<br>Exposure<br>(ug/lb ai) <sup>2</sup> | Inhalation<br>Unit<br>Exposure<br>(ug/lb ai) <sup>2</sup> | Application<br>Rate <sup>3</sup> | Amount<br>Treated<br>Daily <sup>4</sup> | Dose (mg/kg/day) <sup>5</sup> | MOE <sup>6</sup> | Dose (mg/kg/day) <sup>7</sup> | MOE <sup>8</sup> | ARI <sup>9</sup> |
| MIXER/LOADER   |                         |   |   |                                  |   |                               |                  |                               |                  | 1                |
| Mixing / Loading Granules                                      | Baseline                | 8.4   | 1.7   | 0.014 lb                         | 40                                      | 0.000067                      | 1,500,000        | 1.40E-05                      | 590,000          | 570              |
| Spreader Applications  | PPE-G                   | 6.9   | NA  | ai/acre                          | 40 acres                                | 0.000055                      | 1,800,000        | NA                            | NA               | 2,500            |
| APPLICATOR   |                         |   |   |                                  |   |                               |                  |                               |                  |                  |
| Applying Granules via  | Baseline                | 6.6   | 1.2   | 0.014 lb                         | 9                                       | 0.000079                      | 1,300,000        | 9.60E-06                      | 830,000          | 780              |
| Tractor Drawn Spreader   | PPE-G                   | 7.2   | NA  | ai/acre                          | 40 acres                                | 0.000058                      | 1,700,000        | NA                            | NA               | 3,400            |
| Applying Granules by   | Baseline                | 104000  | 470   | 0.017 lb                         | 3 6                                     | 0.013                         | 7,900            | 5.70E-05                      | 140,000          | 51               |
| Hand   | PPE-G                   | 71000   | NA  | ai/acre                          | 0.2 acre                                | 0.0086                        | 12,000           | NA                            | NA               | 100              |
| MIXER/LOADER/APPLICATOR  | CATOR                   |   |   |                                  |   |                               |                  |                               |                  |                  |
| Mixing /   | Baseline                | 440   | 10  | 0.014.15                         |   | 0.00044                       | 230,000          | 1.00E-05                      | 800,000          | 590              |
| Loaumg/Appiymg<br>Granulars via "Push Type"<br>Rotary Spreader | PPE-G                   | 240   | NA  | ai/acre                          | 5 acres                                 | 0.00024                       | 420,000          | NA                            | NA               | 2,000            |
| Applying Ready to Use  | Baseline                | No Data   | 45  | 0.017 lb                         | 0 6                                     | No Data                       | No Data          | 5.50E-06                      | 1,500,000        | No Data          |
| Granular by Spoon (MKIL)<br>452507-01)                         | PPE-G                   | 2000  | NA  | ai/acre                          | U.S acie                                | 0.00024                       | 410,000          | NA                            | NA               | 2,600            |
| Mixing /   | Baseline                | 10000   | 62  | 0.014.15                         |   | 0.002                         | 50,000           | 1.20E-05                      | 650,000          | 280              |
| Coaumg/Appymg<br>Granulars via Belly<br>Grinder                | PPE-G                   | 9300  | NA  | ai/acre                          | 1 acre                                  | 0.0019                        | 54,000           | NA                            | NA               | 460              |

## 5.2 Short- and Intermediate-Term Post-Application Risk

HED uses the term post-application to describe exposures that occur when individuals are present in an environment that has been previously treated with a pesticide (also referred to as reentry exposure). Such exposures may occur when workers enter previously treated areas to perform job functions, including activities related to crop production, such as scouting for pests or harvesting.

## 5.2.1 Dermal Post-Application Risk

Occupational dermal postapplication exposure was not assessed as it is not anticipated that workers will be exposed after application of the fly bait. HED believes the presence of commercial workers in treated areas is minimal after application. A quantitative dermal postapplication assessment has not been conducted.

# 5.2.2 Inhalation Post-Application Risk

Based on the Agency's current practices, a quantitative occupational post-application inhalation exposure assessment was not performed for metaflumizone at this time. However, there are multiple potential sources of post-application inhalation exposure to individuals performing post-application activities in previously treated fields. These potential sources include volatilization of pesticides and resuspension of dusts and/or particulates that contain pesticides. The Agency sought expert advice and input on issues related to volatilization of pesticides from its Federal Insecticide, Fungicide, and Rodenticide Act Scientific Advisory Panel (SAP) in December 2009. The Agency received the SAP's final report on March 2, 2010

(http://www.epa.gov/scipoly/SAP/meetings/2009/120109meeting.html). The Agency is in the process of evaluating the SAP report as well as available post-application inhalation exposure data generated by the Agricultural Reentry Task Force and may, as appropriate, develop policies and procedures, to identify the need for and, subsequently, the way to incorporate occupational post-application inhalation exposure into the Agency's risk assessments. If new policies or procedures are put into place, the Agency may revisit the need for a quantitative occupational post-application inhalation exposure assessment for metaflumizone.

<sup>&</sup>lt;sup>4</sup>Exposure Science Advisory Council Policy #9.1

<sup>&</sup>lt;sup>5</sup> Dermal Dose = Dermal Unit Exposure (mg/kg) × Application Rate (lb ai/acre) × Amount Treated (acres/day) / BW (70 kg)

<sup>&</sup>lt;sup>6</sup> Dermal MOE = Dermal NOAEL (100 mg/kg/day) ÷ Dermal Dose (mg/kg/day). LOC = 100.

<sup>&</sup>lt;sup>7</sup> Inhalation Dose = Dermal Unit Exposure (mg/kg) × Application Rate (lb ai/acre) × Amount Treated (acres/day) ÷ BW (70 kg)

<sup>&</sup>lt;sup>8</sup> Inhalation MOE = Inhalation NOAEL (8 mg/kg/day) ÷ Inhalation Dose (mg/kg/day). LOC = 1000.

<sup>&</sup>lt;sup>9</sup> ARI (Aggregated Risk Index) = 1 / ((1 ÷ (Dermal MOE ÷ LOC<sub>dermal</sub>)) + (1 ÷ (Inhalation MOE ÷ LOC<sub>inhalation</sub>))). Baseline dermal and PPE-G Dermal combined with Baseline Inhalation.



# R196572

Chemical Name: Metaflumizone

PC Code: 281250

**HED File Code:** 12000 Exposure Reviews

Memo Date: 12/20/2011 File ID: 00000000

Accession #: 000-00-0137

HED Records Reference Center 1/5/2012